A multidisciplinary treatment comprising standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for Ewing sarcoma family of tumor (ESFT) in Japan: Results of the first Japan Ewing Sarcoma Study (JESS) 04.
Atsushi Makimoto(Tokyo Metropolitan Children's Medical Center), Toshifumi Ozaki(Okayama University), Michihiro Yano(Akita University), Tsuyoshi Ishida(Kawasaki Medical School), Atsushi Kikuta(Fukushima Medical University), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Motoaki Chin(Nihon University), Yoshifumi Kawano(Kagoshima University), Kazuo Isu(Hokkaido University Hospital), Masahito Hatori(Tohoku University), Ryohei Yokoyama(University of Miyazaki), Masahito Tsurusawa(Aichi Medical University), Hajime Okita(Keio University), Hideaki Ohta(Konan University), Satoshi Morita(Kyoto University), Hiroyoshi Watanabe(Tokushima University), Akinobu Matsuzaki(Kyushu University), Takeshi Ishii(Chiba Cancer Center), Hiroshi Kawamoto(Fujita Health University), Hideo Mugishima(Children's Oncology Group)
Cited by 0
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
|Annals of Oncology|2012|555
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
|Journal of Clinical Oncology|2009|516
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
|Journal of Clinical Oncology|2019|490